Thomas Jacobsen
Net worth: 23 M $ as of 2026-05-30
Net worth: 23 M $ as of 2026-05-30
Thomas Jacobsen is the founder of Hyloris Pharmaceuticals SA, founded in 2012, holding the title of Executive Director since 2025.
Mr. Jacobsen is also the founder of Alter Pharma Group NV..
Mr. Jacobsen currently holds the position of Director at Hyloris Developments SA since 2020.
Mr. Jacobsen completed undergraduate studies at Copenhagen Business School and graduate studies at the University of Copenhagen.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-12-30 | 3,857,838 ( 13.78% ) | 23 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| HYLORIS PHARMACEUTICALS SA | Founder | 2011-12-31 |
Hyloris Developments SA
Hyloris Developments SA Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products | Director/Board Member | 2020-04-19 |
| Companies | Position | End |
|---|---|---|
Alter Pharma Group NV
Alter Pharma Group NV Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Founder | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 5 |
|---|---|
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alter Pharma Group NV
Alter Pharma Group NV Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products by reformulating well-known drugs | Health Technology |
Hyloris Developments SA
Hyloris Developments SA Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions